{"category": "ham", "to_address": "Spielas Bates <bates@stat.wisc.edu>,\n   Nicholas Lewin-Koh <nikko@hailmail.net>", "from_address": "John Kane <jrkrideau@yahoo.ca>", "subject": "Re: [R] R vs. Splus in Pharma/Devices Industry", "body": "\n--- Spielas Bates  wrote:\n\n> On 6/15/07, Nicholas Lewin-Koh \n> wrote:\n> > Hi,\n> > I just saw this thread. This issue, and the larger\n> scale issue of open\n> > source in industry\n> > is being addressed. One has to realize that the\n> behemoth that is the\n> > clinical aperatus\n> > of the pharma industry is very conservative and\n> very slow to change. In\n> > many cases\n> > switching to R would meean changing a great many\n> processes all based on\n> > legacy code. One\n> > of the big issues is that the industry demands\n> consistency not\n> > necessarily correctness.\n> >\n> > All that said there are a great many areas where R\n> could be used that\n> > would not impact\n> > regulatory submission, data security etc. Many in\n> pharma are quietly\n> > working on this,\n> > but steps are small and incremental. Development\n> takes time in industry\n> > because of the amount of\n> > documentation necessary. All this impacts the\n> \"free\" nature of R and\n> > cost and risk (From the industries\n> > perspective) need to be justified.\n> \n> > Probably when the statistical community is using Z\n> big pharma will be\n> > ready to use\n> > R. %P\n> \n> I think you mean A, not Z.  First there was S, then\n> there was R.\n\nWe're regressing !!!!\n\n______________________________________________\nR-help@stat.math.ethz.ch mailing list\nhttps://stat.ethz.ch/mailman/listinfo/r-help\nPLEASE do read the posting guide http://www.R-project.org/posting-guide.html\nand provide commented, minimal, self-contained, reproducible code.\n\n"}